Towson, Maryland Clinical Trials

A listing of Towson, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

local therapy
cancer
adenocarcinoma of prostate
metastasis
testosterone
Johns Hopkins University
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

anticancer agents
solid tumors
cancer
hematopoietic growth factors
non-hodgkin lymphoma
Sinai Hospital of Baltimore
 (6.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

measurable disease
nf2 gene
multiple meningiomas
neutrophil count
crizotinib
Johns Hopkins University (Site 250)
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF

This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction (HFpEF).

left ventricular end-diastolic pressure
fibrillation
atrial fibrillation
b-type natriuretic peptide
heart failure
Johns Hopkins Hospital
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

This phase II trial studies how well infliximab and intravenous immunoglobulin therapy work in treating patients with pneumonitis that does not respond to steroid treatment. Immunotherapy with monoclonal antibodies such as, infliximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow …

cancer
pneumonia
igiv
oophorectomy
blood test
Jarushka Naidoo
 (9.6 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Effects of tDCS on Apraxia of Speech in Non-Fluent Primary Progressive Aphasia

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. There are three different variants of PPA, each a relatively distinct speech and language profile. For individuals with non-fluent variant PPA (nfvPPA), a core symptom is apraxia of speech (AOS), which is defined as an …

transcranial direct current stimulation
aphasia
neurodegenerative disorder
apraxia of speech
language testing
Johns Hopkins Hospital
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

A single-arm, two-stage, open-label, phase 2 study investigating the safety and efficacy of intravesical gemcitabine/docetaxel for bacillus Calmette-Guerin (BCG)-nave patients with non-muscle invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to providing initial …

transitional cell carcinoma of bladder
hormone levels
carcinoma
bcg vaccine
cancer
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
taxane
castration-resistant prostate cancer
cancer
prostatic neoplasm
Johns Hopkins University
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

tremor
methyldopa
parkinson's disease
muscle rigidity
modafinil
John Hopkins University
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations
Proton Radiation Therapy Registry

The Johns Hopkins Proton Therapy center is establishing a registry to capture the full 3D radiation dosimetry delivered to the patient, baseline clinical data, and disease, toxicity and quality of life outcomes. The goal is to have all patients treated at the proton center to be included in the registry …

Johns Hopkins Hospital
 (7.7 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +3 other locations